非小细胞肺癌表皮生长因子受体靶向治疗的研究进展  

Molecular basis of variability in EGFR⁃targeted therapy response in non⁃small cell lung cancer

作　　者：李玉婷 颜琦璐 宋启斌[1] LI Yut-ing;YAN Qilu;SONG Qibin(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《实用医学杂志》2024年第15期2166-2171,共6页The Journal of Practical Medicine

基　　金：国家自然科学基金项目(编号:82273094)。

摘　　要：肺癌是致死率最高的恶性肿瘤,非小细胞肺癌(NSCLC)是最主要的病理类型。表皮生长因子受体(EGFR)的突变驱动NSCLC的发展,而表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)是晚期EGFR突变NSCLC患者的标准一线治疗。然而,分子结构、伴随突变和耐药机制等多个维度的不同机制,导致了EGFR亚组的预后差异。本文主要综述NSCLC中EGFR不同突变类型的分子结构基础与治疗反应差异。Lung cancer is the most fatal malignant tumor worldwide,with non-small cell lung cancer(NSCLC)being the predominant pathological subtype.The development of NSCLC is driven by mutations in the epidermal growth factor receptor(EGFR),and EGFR tyrosine kinase inhibitors(EGFR-TKIs)are employed as targeted therapies for first-line treatment of advanced NSCLC patients harboring EGFR mutations.However,variations in molecular structures,concurrent mutations,and mechanisms of therapeutic resistance contribute to prognostic disparities among different EGFR subgroups.This review primarily summarizes the molecular structural basis and differential treatment responses associated with distinct types of EGFR mutations in NSCLC.

关 键 词：非小细胞肺癌 EGFR突变 靶向治疗 分子结构 

分 类 号：R734.2[医药卫生—肿瘤]